Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels

Journal of Diabetes

Volumn 8, Issue 4, 2016, Pages 559-567

  Zhang, Jin Ping ^a   Wang, Na ^b   Xing, Xiao Yan ^b   Yang, Zhao Jun ^b   Wang, Xin ^b   Yang, Wen Ying ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

acarbose; HbA1c; metformin; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; CHOLESTEROL; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84973855895     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12337     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position sttement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364–79.
2. Li R, Lu W, Jian QW et al. Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. Diabetes Care. 2012; 35: 1028–30.
3. Yu X, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948–59.
4. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician. 2009; 79: 29–36.
5. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014; 11: 1185–200.
6. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs. 2005; 65: 385–411.
7. Yang WY, Liu J, Shan ZG et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: An open-label, non-inferiority randomised trial. Lancet Diabetes-Endocrinology. 2014; 2: 46–55.
8. Wang G, Liu J, Yang N et al. MARCH2: Comparative assessment of theraprutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients. PLoS One. 2014; 9e105698.
9. World Health Organization (WHO). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, WHO, 1999.
10. Yang WY, Weng JP. Early therapy for type 2 diabetes in China. Lancet Diabetes-Endocrinology. 2014; 2: 46–55. DOI:10.1016/52213-8587(14)70136-6.
11. Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090–101.
12. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004; 47: 385–94.
13. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003; 290: 486–94.
14. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J. 2004; 25: 10–6.
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 854–65.